4.4 Review

Mechanisms Underlying Non-Pharmacological Dementia Prevention Strategies: A Translational Perspective

Journal

Publisher

SPRINGER BASEL AG
DOI: 10.14283/jpad.2022.9

Keywords

Alzheimer's disease; dementia; prevention; mouse models; multidomain; lifestyle

Funding

  1. Center for Innovative Medicine (CIMED) at Flemingsberg Campus
  2. Stiftelsen Stockholms sjukhem, Sweden
  3. Knut and Alice Wallenberg Foundation
  4. Gun och Bertil Stohnes Stiftelse
  5. Demensfonden
  6. Swedish Research Council

Ask authors/readers for more resources

Modifying lifestyle can prevent and improve Alzheimer's disease and cognitive impairment. Implementing different types of lifestyle interventions on animal models can improve cognitive abilities, alleviate pathology and inflammation, restore mitochondrial function, and have a positive impact on neurogenesis and cell survival. Although some important pathways have been identified, further research is needed to confirm these mechanisms of action.
Since developing an effective treatment for Alzheimer's disease (AD) has been encountered as a challenging task, attempts to prevent cognitive decline by lifestyle modifications have become increasingly appealing. Physical exercise, healthy diet, and cognitive training are all modifiable, non-pharmacological lifestyle factors considered to influence cognitive health. Implementing lifestyle modifications on animal models of AD and cognitive impairment may reveal underlying mechanisms of action by which healthy lifestyle contribute to brain health. In mice, different types of lifestyle interventions have been shown to improve cognitive abilities, alleviate AD-related pathology and neuroinflammation, restore mitochondrial function, and have a positive impact on neurogenesis and cell survival. Different proteins and pathways have been identified to mediate some of the responses, amongst them BDNF, Akt-GSK3 beta, JNK, and ROCK pathway. Although some important pathways have been identified as mediating improvements in brain health, more research is needed to confirm these mechanisms of action and to improve the understanding of their interplay. Moreover, multidomain lifestyle interventions targeting multiple risk factors simultaneously may be a promising avenue in future dementia prevention strategies. Therefore, future work is needed to better understand the synergistic impact of combinatory lifestyle strategies on cellular mechanisms and brain health.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Evidence-Based Tools for Dietary Assessments in Nutrition Epidemiology Studies for Dementia Prevention

K. A. Abbott, J. M. Posma, S. Garcia-Perez, C. Udeh-Momoh, S. Ahmadi-Abhari, L. Middleton, G. Frost

Summary: Diet is an important modifiable factor in reducing the risk of Alzheimer's Disease and age-related cognitive decline. However, accurate assessment of dietary exposures is challenging due to misreporting and measurement errors. The use of -omics technologies can improve reliability and provide new insights into pre-disease indicators and preventive targets for cognitive aging and dementia.

JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2022)

Article Clinical Neurology

At a Glance: An Update on Neuroimaging and Retinal Imaging in Alzheimer's Disease and Related Research

J. Ford, D. Kafetsouli, H. Wilson, C. Udeh-Momoh, M. Politis, S. AhmadiAbhari, I Rabiner, L. T. Middleton

Summary: Neuroimaging plays a crucial role in Alzheimer's disease and related dementia research, helping us understand the brain's structure, function, and disease progression. Technological advancements in this field have provided powerful tools to visualize and study the brain, bringing us closer to the goal of dementia prevention.

JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2022)

Article Clinical Neurology

Associations of Cardiovascular and Non-Cardiovascular Comorbidities with Dementia Risk in Patients with Diabetes: Results from a Large UK Cohort Study

B. Zheng, B. Su, C. Udeh-Momoh, G. Price, I Tzoulaki, E. P. Vamos, A. Majeed, E. Riboli, S. Ahmadi-Abhari, L. T. Middleton

Summary: This study found that cardiovascular and non-cardiovascular comorbidities in patients with type 2 diabetes are associated with an increased risk of dementia. Preventing and effectively managing these comorbidities is crucial for maintaining cognitive health in patients with diabetes.

JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2022)

Editorial Material Clinical Neurology

Dementia Prevention: A Global Challenge in Urgent Need of Solutions

G. Price, C. Udeh-Momoh, M. Kivipelto, Lefkos T. Middleton

JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2022)

Review Clinical Neurology

New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia

Martha del Campo, Henrik Zetterberg, Sam Gandy, Chiadi U. Onyike, Fabricio Oliveira, Chi Udeh-Momoh, Alberto Lleo, Charlotte E. Teunissen, Yolande Pijnenburg

Summary: Frontotemporal dementia (FTD) is a neurodegenerative disorder with diverse clinical and pathological features. The development of specific diagnostic biomarkers, disease staging markers, and treatment response markers is important but challenging.

ALZHEIMERS & DEMENTIA (2022)

Article Clinical Neurology

Blood β-synuclein is related to amyloid PET positivity in memory clinic patients

Patrick Oeckl, Marina Bluma, Marco Bucci, Steffen Halbgebauer, Konstantinos Chiotis, Anna Sandebring-Matton, Nicholas J. Ashton, Guglielmo Di Molfetta, Lana Grotschel, Miia Kivipelto, Kaj Blennow, Henrik Zetterberg, Irina Savitcheva, Agneta Nordberg, Markus Otto

Summary: Plasma beta-synuclein levels were found to be higher in individuals with Alzheimer's disease and mild cognitive impairment with amyloid-beta positivity. It demonstrated good discrimination and prediction of amyloid-beta status. The correlation between plasma beta-synuclein and amyloid-beta PET was observed in multiple cortical regions. These findings suggest that beta-synuclein is not a direct marker of amyloid-beta pathology and highlight the different longitudinal dynamics of synaptic degeneration and amyloid deposition in Alzheimer's disease.

ALZHEIMERS & DEMENTIA (2023)

Editorial Material Clinical Neurology

The Nairobi Declaration-Reducing the burden of dementia in low- and middle-income countries (LMICs): Declaration of the 2022 Symposium on Dementia and Brain Aging in LMICs

Gladys Maestre, Maria Carrillo, Raj Kalaria, Daisy Acosta, Larry Adams, Thierry Adoukonou, Kazeem Akinwande, Joshua Akinyemi, Rufus Akinyemi, Onoja Akpa, Suvarna Alladi, Ricardo Allegri, Raul Arizaga, Faheem Arshad, Oyedunni Arulogun, David Ndetei, Olusegun Baiyewu, Thomas Issac, Tarek Bellaj, Judith Boshe, Carol Brayne, David Brodie-Mends, Richard Brown, Jennifer Cahn, Nkouonlack Cyrille, Albertino Damasceno, Ranil de Silva, Rohan de Silva, Mamuka Djibuti, Anna Jane Dreyer, Ratnavalli Ellajosyula, Temitope Farombi, Bernard Fongang, Stefania Forner, Rob Friedland, Noe Garza, Antoine Gbessemehlan, Eliza (Eleni-Zacharoula) Georgiou, Riadh Gouider, Ishtar Govia, Lea Grinberg, Maelenn Guerchet, Seid Gugssa, Joy Louise Gumikiriza-Onoria, Deborah Gustafson, Eef Hogervorst, Michael Hornberger, Agustin Ibanez, Masafumi Ihara, Ozama Ismail, Thomas Issac, Linus Joensson, Celestin Kaputu, Wambui Karanja, Jackline Karungi, Desire Tshala-Katumbay, Brian Kunkle, Joseph H. Lee, Iracema Leroi, Raphaella Lewis, Gill Livingston, Francisco Lopera, Kamada Lwere, Facundo Manes, Lingani Mbakile-Mahlanza, Pedro Mena, Bruce Miller, Athanase Millogo, Abdul Mohamed, Christine Musyimi, Victoria Mutiso, Noeline Nakasujja, David Ndetei, Sam Nightingale, Alfred K. Njamnshi, Gabriela Novotni, Primrose Nyamayaro, Solomon Nyame, Julius Ogeng'o, Adesola Ogunniyi, Maira Okada De Oliveira, Njideka Okubadejo, Martin Orrell, Akintunde Orunmuyi, Mayowa Owolabi, Stella Paddick, Margaret A. Pericak-Vance, Zvezdan Pirtosek, Felix Potocnik, Bill Preston, Rema Raman, Kirti Ranchod, Mie Rizig, Monica Rosselli, Roy Deepa, Upal Roy, Marufjon Salokhiddinov, Mary Sano, Fred Sarfo, Claudia L. Satizabal, Diego Sepulveda-Falla, Sudha Seshadri, Claire Sexton, Ingmar Skoog, Peter St George-Hyslop, Claudia Suemoto, Jeremy Tanner, Prekshya Thapa, Kamadore Toure, Valentine Ucheagwu, Chinedu Udeh-Momoh, Victor Valcour, Jeffery Vance, Mathew Varghese, Jaime Vera, Richard Walker, Wendy Weidner, Walsh Sebastian, Patrice Whitehead Gay, Henrik Zetterberg, Yared Zewde

ALZHEIMERS & DEMENTIA (2023)

Review Public, Environmental & Occupational Health

Diabetes mellitus, prediabetes and the risk of Parkinson's disease: a systematic review and meta-analysis of 15 cohort studies with 29.9 million participants and 86,345 cases

Dagfinn Aune, Sabrina Schlesinger, Yahya Mahamat-Saleh, Bang Zheng, Chinedu T. T. Udeh-Momoh, Lefkos T. T. Middleton

Summary: A systematic review and meta-analysis found that diabetes mellitus and prediabetes were associated with an increased risk of developing Parkinson's disease. This association was consistent across different geographic regions, sexes, and subgroups, and diabetes patients with complications had a higher risk. Further research is needed to investigate the role of age of onset, duration, complications, glycemic level, and management of diabetes in relation to Parkinson's disease risk.

EUROPEAN JOURNAL OF EPIDEMIOLOGY (2023)

Article Neurosciences

27-hydroxycholesterol promotes oligodendrocyte maturation: Implications for hypercholesterolemia-associated brain white matter changes

Vilma Alanko, Adhara Gaminde-Blasco, Tania Quintela-Lopez, Raul Loera-Valencia, Alina Solomon, Ingemar Bjorkhem, Angel Cedazo-Minguez, Silvia Maioli, Graziella Tabacaru, Maria Latorre-Leal, Carlos Matute, Miia Kivipelto, Elena Alberdi, Anna Sandebring-Matton

Summary: Oxidized cholesterol metabolite 27-hydroxycholesterol (27-OH) is a potential link between hypercholesterolemia and neurodegenerative diseases as it can cross the blood-brain barrier. This study found that high levels of 27-OH can impact oligodendrocyte function and contribute to the disconnection of neural networks in neurodegenerative diseases.
Article Immunology

Longitudinal study of Alzheimer's disease biomarkers, allostatic load, and cognition among memory clinic patients

Dickson O. Adedeji, Jasper Holleman, Robert-Paul Juster, Chinedu T. Udeh-Momoh, Ingemar Kareholt, Goran Hagman, Malin Aspo, Sofia Adagunodo, Krister Hakansson, Miia Kivipelto, Alina Solomon, Shireen Sindi

Summary: This study aims to assess the association between allostatic load (AL) and Alzheimer's disease (AD) biomarkers as well as cognitive function. The results showed that higher AL was associated with increased brain amyloid accumulation, suggesting that AL may play a role in the pathophysiology of AD/dementia.

BRAIN, BEHAVIOR, & IMMUNITY - HEALTH (2023)

Article Clinical Neurology

Association of Blood MicroRNA Expression and Polymorphisms with Cognitive and Biomarker Changes in Older Adults

A. Sadlon, P. Takousis, E. Evangelou, I. Prokopenko, P. Alexopoulos, C. -M. Udeh-Momoh, G. Price, L. Middleton, Robert Perneczky

Summary: Investigating miRNA as a blood biomarker for early cognitive decline in older adults is important for identifying individuals with Alzheimer's disease (AD) before symptoms appear. The study found that six miRNAs were downregulated in the blood of individuals with low cognitive performance, indicating involvement of apoptosis and inflammation in early stages of AD. Polymorphisms within these miRNAs were associated with CSF levels of amyloid-beta 42, soluble-TREM2, and BACE1 activity.

JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2023)

Article Cell Biology

Sex and gender considerations in dementia: a call for global research

Clara Vila-Castelar, Chinedu Udeh-Momoh, Neelum T. Aggarwal, Michelle M. Mielke

Summary: Studies have found sex and/or gender differences in Alzheimer's disease, but little research has been conducted on other dementias. This article highlights the sex and gender differences in other forms of dementia, explores sociocultural factors, and provides a framework for future global studies.

NATURE AGING (2023)

Article Clinical Neurology

Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention

C. Udeh-Momoh, B. Zheng, A. Sandebring-Matton, G. Novak, M. Kivipelto, L. Jonsson, L. Middleton

Summary: This study validated the capacity of plasma A beta 42/A beta 40 measured using six different assays to predict amyloid positivity in cognitively unimpaired participants and discriminating between cognitively unimpaired and Alzheimer's disease cases. The use of ultrasensitive immunoassays and high-performance immunoprecipitation coupled with mass spectrometry for measurement of plasma A beta 42/A beta 40 showed diagnostic value in detecting PET amyloid positivity, with potential clinical utility in AD prevention trials and clinical care.

JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2022)

No Data Available